Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 5 studies | 18% ± 3% | |
glutamatergic neuron | 3 studies | 31% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 23% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 694.29 | 653 / 653 | 100% | 9.60 | 603 / 605 |
breast | 100% | 467.68 | 459 / 459 | 99% | 8.46 | 1110 / 1118 |
brain | 99% | 369.86 | 2626 / 2642 | 100% | 7.27 | 703 / 705 |
intestine | 100% | 721.65 | 966 / 966 | 99% | 8.59 | 522 / 527 |
prostate | 100% | 489.62 | 244 / 245 | 99% | 7.19 | 497 / 502 |
pancreas | 99% | 315.27 | 326 / 328 | 98% | 6.11 | 175 / 178 |
kidney | 100% | 687.84 | 89 / 89 | 98% | 7.82 | 880 / 901 |
stomach | 99% | 393.67 | 356 / 359 | 98% | 7.40 | 280 / 286 |
bladder | 100% | 496.86 | 21 / 21 | 97% | 6.65 | 488 / 504 |
uterus | 100% | 427.93 | 170 / 170 | 96% | 6.76 | 440 / 459 |
skin | 100% | 606.85 | 1806 / 1809 | 96% | 9.14 | 451 / 472 |
ovary | 100% | 313.35 | 180 / 180 | 94% | 4.96 | 405 / 430 |
esophagus | 100% | 574.91 | 1444 / 1445 | 94% | 5.21 | 172 / 183 |
lung | 95% | 376.84 | 549 / 578 | 97% | 5.42 | 1115 / 1155 |
liver | 100% | 468.21 | 226 / 226 | 88% | 4.08 | 356 / 406 |
adrenal gland | 100% | 812.64 | 257 / 258 | 87% | 4.65 | 200 / 230 |
spleen | 100% | 543.78 | 241 / 241 | 0% | 0 | 0 / 0 |
muscle | 100% | 1072.65 | 802 / 803 | 0% | 0 | 0 / 0 |
adipose | 100% | 476.26 | 1201 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 370.28 | 1328 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 799.28 | 855 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 7.28 | 44 / 45 |
lymph node | 0% | 0 | 0 / 0 | 97% | 5.84 | 28 / 29 |
eye | 0% | 0 | 0 / 0 | 95% | 10.84 | 76 / 80 |
peripheral blood | 82% | 475.52 | 766 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0009435 | Biological process | NAD biosynthetic process |
GO_0009165 | Biological process | nucleotide biosynthetic process |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0009611 | Biological process | response to wounding |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0043524 | Biological process | negative regulation of neuron apoptotic process |
GO_1902511 | Biological process | negative regulation of apoptotic DNA fragmentation |
GO_1990966 | Biological process | ATP generation from poly-ADP-D-ribose |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016604 | Cellular component | nuclear body |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000309 | Molecular function | nicotinamide-nucleotide adenylyltransferase activity |
GO_0004515 | Molecular function | nicotinate-nucleotide adenylyltransferase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0140768 | Molecular function | protein ADP-ribosyltransferase-substrate adaptor activity |
GO_0005524 | Molecular function | ATP binding |
Gene name | NMNAT1 |
Protein name | Nicotinamide nucleotide adenylyltransferase 1 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 (NMN/NaMN adenylyltransferase 1) (EC 2.7.7.1) (EC 2.7.7.18) (Nicotinamide-nucleotide adenylyltransferase 1) (NMN adenylyltransferase 1) (Nicotinate-nucleotide adenylyltransferase 1) (NaMN adenylyltransferase 1) |
Synonyms | NMNAT |
Description | FUNCTION: Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP . Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency . Can use triazofurin monophosphate (TrMP) as substrate . Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+) . For the pyrophosphorolytic activity, prefers NAD(+) and NaAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively . Involved in the synthesis of ATP in the nucleus, together with PARP1, PARG and NUDT5 . Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming . Also acts as a cofactor for glutamate and aspartate ADP-ribosylation by directing PARP1 catalytic activity to glutamate and aspartate residues on histones (By similarity). Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+) . Protects against axonal degeneration following mechanical or toxic insults (By similarity). . |
Accessions | Q9HAN9 ENST00000403197.5 ENST00000462686.1 ENST00000377205.6 ENST00000496751.1 K7EPD7 B1AN62 |